Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
| ▸ | THRA | P10827 | 1/20 | 0.44 |
| ▸ | LPL | P06858 | 5/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29954116 | 0.97 | NR5A1 (0.49) | CA1CA2CA12CA3CA4 | |
| SCHEMBL4748948 | 0.95 | NR5A1 (0.51) | CA1CA2THRALPLLIPG | |
| SCHEMBL8505542 | 0.95 | NR5A1 (0.51) | CA1CA2THRALPLLIPG | |
| SCHEMBL4748959 | 0.95 | NR5A1 (0.51) | CA1CA2THRALPLLIPG | |
| SCHEMBL5854005 | 0.86 | CA1 (0.48) | CA1CA2CA12CA9 | |
| SCHEMBL8514 | 0.86 | CA1 (0.52) | CA1CA2CA12CA4CA6 | |
| SCHEMBL29953867 | 0.86 | CA1 (0.52) | CA1CA2CA12CA4CA6 | |
| SCHEMBL2559249 | 0.85 | CA1 (0.47) | CA1CA2 | |
| SCHEMBL9986418 | 0.84 | CA1 (0.50) | CA1CA2CA12CA4CA9 | |
| SCHEMBL623764 | 0.83 | CA1 (0.57) | CA1CA2LPLLIPGLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2784055-A1 | Fluoroform synthesis and uses thereof in the preparation of trifluoromethylated compounds | Institut National des Sciences Appliquées de Rouen (INSA) (FR) | 2014-10-01 | — | — | EP | disclosed |
| EP-2065383-A1 | Indazole compounds and methods of use thereof as protein kinase inhibitors | Signal Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | BHAGWAT SHRIPAD S | 2009-04-16 | — | — | US | disclosed |
| EP-1692128-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | Signal Pharmaceuticals LLC (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | BHAGWAT SHRIPAD S | 2006-01-05 | — | — | US | disclosed |
| WO-2005051942-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2005-06-09 | — | — | WO | disclosed |
| EP-0531475-B1 | NAPHTHYL ORGANIC COMPOUNDS | QINETIQ LTD (GB) | 2002-08-28 | — | — | EP | disclosed |
| US-20020011588-A1 | Naphthyl organic compounds | QINETIQ LIMITED (GB) | 2002-01-31 | — | — | US | disclosed |
| US-6291034-B1 | LIQUID CRYSTALLINE MATERIAL | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) | 2001-09-18 | — | — | US | disclosed |
| US-5820781-A | Naphthyl organic compounds | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN & NORTHERN IRELAND (GB) | 1998-10-13 | — | — | US | disclosed |
| US-5496500-A | LIQUID CRYSTALS; ELECTROOPTICS DISPLAY DEVICES; DROPLETS DISPERSED IN TRANSPARENT POLYMER MATRIX | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN & NORTHERN IRELAND (GB) | 1996-03-05 | — | — | US | disclosed |
| EP-0531475-A1 | NAPHTHYL ORGANIC COMPOUNDS | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN (GB) | 1993-03-17 | — | — | EP | disclosed |
| WO-1992016500-A1 | NAPHTHYL ORGANIC COMPOUNDS | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) | 1992-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | WNT3, WNT3A, WNK3 | CA1 3293/4885CA2 1269/4885CA12 3384/4885 |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | WNT3, WNT3A, WNK3 | CA1 3295/4885CA2 1341/4885CA12 3349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.